Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...
Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza ...
Health insurance coverage for GLP-1 drugs isn't getting better despite surging demand from Americans looking to lose weight or treat Type 2 diabetes. The percentage of patients with no insurance ...
Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK.
THURSDAY, March 6, 2025 (HealthDay News) -- GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study suggests. The drugs help manage patients ...
"This finding suggests that it may be beneficial to reassess the preoperative withholding guidelines for GLP-1 RAs." HealthDay News — Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback